The ESMO 20th World Congress on Gastrointestinal Cancer represents the year’s most important meeting, designed to focus on reversing the current global statistics that rank gastrointestinal malignancies as one of the leading causes of cancer deaths worldwide.

As the premier global event in the field, the Congress brings together leading gastroenterology, oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe to share pioneering research, approaches, and best practices for treating patients with cancers of the gastrointestinal tract.

The program provides all stakeholders with opportunities to learn, debate, discuss, and network in this very active scientific field where recent progress has led to improvements in patient outcomes.

Join us, and your global colleagues, for this important milestone highlighting more than two decades of groundbreaking research and innovation.

CHAIR
Mario Dicato
MD
LUXEMBOURG, LUXEMBOURG

CHAIR
Eric Van Cutsem
MD, PHD
LEUVEN, BELGIUM

VICE CHAIR
Josep Tabernero
MD, PHD
BARCELONA, SPAIN
3,500 Delegates
120 Countries
21 Sessions

SCIENTIFIC COMMITTEE

Nadir Arber, MD, MSc, MHA
Tel Aviv Medical Center
Tel Aviv University
Tel Aviv, Israel

Regina G.H. Beets-Tan, MD, PhD
Maastricht University Medical Center
Maastricht, The Netherlands

Jordan D. Berlin, MD
Vanderbilt University Medical Center
Nashville, United States

Fatima Carneiro, MD, PhD
IPATIMUP & Medical Faculty
Porto, Portugal

Mario Dicato, MD
Congress Chair
Luxembourg Medical Center
Luxembourg, Luxembourg

Axel Grothey, MD
Mayo Clinic
Rochester, United States

Karin Haustermans, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Brigette Ma, MD
Chinese University of Hong Kong
Hong Kong, Hong Kong

Erika Martinelli, MD, PhD
Second University of Naples
Naples, Italy

Bernard Nordlinger, MD
Hôpital Ambroise-Paré
Boulogne, France

Eileen O'Reilly, MD
Memorial Sloan Kettering Cancer Center
New York, United States

Jaroslaw Regula, MD, PhD
Maria Sklodowska Curie
Memorial Cancer Centre Institute of Oncology
Warsaw, Poland

Rachel Riechelmann, MD
Instituto do Cancer do Estado de São Paulo
University of São Paulo
São Paulo, Brazil

Thomas Seufferlein, MD
Ulm University
Ulm, Germany

Ali Shamseddine, MD, FRCP
American University of Beirut Medical Center
Beirut, Lebanon

Andrés Cervantes, MD, PhD
ESMO Representative
University of Valencia INCLIVA
Valencia, Spain

Fortunato Ciardiello, MD, PhD
ESMO Representative
Second University of Naples
Naples, Italy

Jorge Gallardo, MD
Hospital Clínico José Joaquín Aguirre
Universidad de Chile
Santiago, Chile

Andrés Cervantes,
MD, PhD
ESMO Representative
University of Valencia INCLIVA
Valencia, Spain

Fatima Carneiro, MD, PhD
IPATIMUP & Medical Faculty
Porto, Portugal

Mario Dicato, MD
Congress Chair
Luxembourg Medical Center
Luxembourg, Luxembourg

Axel Grothey, MD
Mayo Clinic
Rochester, United States

Karin Haustermans, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Brigette Ma, MD
Chinese University of Hong Kong
Hong Kong, Hong Kong

Erika Martinelli, MD, PhD
Second University of Naples
Naples, Italy

Bernard Nordlinger, MD
Hôpital Ambroise-Paré
Boulogne, France

Eileen O'Reilly, MD
Memorial Sloan Kettering Cancer Center
New York, United States

Jaroslaw Regula, MD, PhD
Maria Sklodowska Curie
Memorial Cancer Centre Institute of Oncology
Warsaw, Poland

Rachel Riechelmann, MD
Instituto do Cancer do Estado de São Paulo
University of São Paulo
São Paulo, Brazil

Thomas Seufferlein, MD
Ulm University
Ulm, Germany

Ali Shamseddine, MD, FRCP
American University of Beirut Medical Center
Beirut, Lebanon

Alberto Sobrero, MD
ESMO Representative
IRCCS Ospedale San Martino IST
Genova, Italy

Josep Tabernero, MD, PhD
ESMO Representative
Congress Vice Chair
Vall d’Hebron University Hospital
Barcelona, Spain

Eric Van Cutsem, MD, PhD
Congress Chair
University Hospital Gasthuisberg
Leuven, Belgium

Takayuki Yoshino, MD
National Cancer Center Hospital East
Chiba, Japan
The following topics will be presented through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations.

Cancer of the Pancreas
Genetics in pancreatic cancer: implications for clinical practice
Are we making progress in surgery of the pancreas?
Is adjuvant or neo-adjuvant treatment for resectable pancreatic cancer the way to go?
Adjuvant treatment of pancreatic cancer: Monotherapy or combination chemotherapy
Improving the outcomes of patients with metastatic pancreatic cancer
New agents/strategies on the horizon in bile duct cancer

Meet the Expert Presentations
New endoscopic screening tools: NBI, chromoendoscopy—How do they help us?
Advances in surgery of rectal cancer
Carcinoma of unknown origin
Teaching on new evolutions in radiation oncology
ESMO Session: Focus on Young Medical Oncologists

Interpreting Clinical Trial Results
Do nomograms help us to predict early mortality and survival? How useful are they?
Clinical interpretation and validity of clinical trials: When do they become practice-changing?
What to use to improve the evaluation of responses: RECIST, mRECIST, iRECIST, or other?

Esophageal and Gastric Cancers
Management of squamous cell cancer for the esophagus
Definitive CRT or neoadjuvant therapy followed by surgery
Locally advanced GE junction cancer: CRT or perioperative CT
Progress in unraveling the molecular taxonomy in esophageal and gastric cancer

Gastric Cancer
Metastatic gastric cancer: Where are we with checkpoint inhibitors in gastric cancer?
Hereditary aspects of gastric cancer
Metastatic gastric cancer: New targeted agents in metastatic gastric cancer

Diseases & Cancers of the Liver
Progress in liver transplantation in GI malignancies: HCC, biliary tract, NET
How to integrate new agents in HCC?
Case-based Workshop: Locoregional treatment for liver metastases: How to choose within the toolbox and when to go for locoregional treatments
Multidisciplinary tumor board on HCC and borderline/potentially resectable liver metastases

Expert Highlights: What is New in This Disease?
What is new in NET?
What is new in GIST?
What is new in anal cancer?
What is new in bile duct cancer?

Prevention and Screening of Colon Cancer
Genetic testing for familial and hereditary colorectal cancer
Screening for colon cancer: What has been achieved in 2018 & new prospects?
Will chemoprevention become a reality?

Multimodality Therapy for Rectal Cancer
TME surgery as seen by the creator
Lymph nodes are relevant in the preoperative evaluation: No, they are not relevant, or Yes, of course
Rectal cancer after neoadjuvant therapy with complete clinical response: Surgery or watchful waiting
New evolutions and ideas in surgery
Adjuvant chemotherapy in rectal cancer

Molecular Biology in CRC
How to approach the patient with a BRAF mutant tumor
Current status and perspectives on liquid biopsies in GI cancer
Is circulating DNA relevant in stage II colon cancer?
New insights on the molecular and immunologic classifications in CRC
Is broad NGS testing useful in my patients with metastatic colorectal cancer?

Immune Mechanisms and Immune Therapy in GI Cancer
How to improve the results with IO agents in MSI GI cancer
How can we increase the immunogenicity in MSS CRC?
Are we making progress with IO in pancreatic cancer?

Understanding Treatment Influences
How can we deal with the explosion of new treatments?
FDA
EMA
Industry
Patient advocacy
Cost & health economics

Colorectal Cancer
The microbiome in colon cancer
Updates on treatment algorithms in metastatic CRC in 2018
The left versus right colon cancer story: What is the truth?
Can we refine the selection for adjuvant treatment in stage III colon cancer?
Can we refine the selection for adjuvant treatment in stage II colon cancer?

Clinical Updates
The history of GI cancer: What has been achieved over the last 20 years?
Molecular and hereditary tumor board
What do the new evolutions in GI cancer mean for my practice in South America, the Middle East, and Asia?
Registration
Accommodations
CONGRESS LOCATION
The International Convention Center of Barcelona
Centre de Convenciones Internacional de Barcelona (CCIB)
Plaça de Willy Brandt 11-14
08019 Barcelona, Spain

WHO SHOULD ATTEND
This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

LEARNING OBJECTIVES
After attending this Congress, participants should be able to:

- Identify current controversies in the management of patients with gastric or esophageal cancers
- Discuss contemporary treatment options for patients with gastric or esophageal cancers
- Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
- Describe the epidemiology and pathogenesis of hepatocellular carcinoma
- Discuss management of patients with cancer of the liver
- Identify adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
- Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
- Describe the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
- Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
- Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results

REGISTRATION RATES

<table>
<thead>
<tr>
<th></th>
<th>NON-MEMBER RATE</th>
<th>ESMO MEMBER RATE*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>€700</td>
<td>€560</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€815</td>
<td>€640</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant*</td>
<td>€400</td>
<td>€320</td>
</tr>
<tr>
<td><strong>DISCOUNTED 12 April—31 May 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physicians</td>
<td>€800</td>
<td>€640</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€715</td>
<td>€570</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant*</td>
<td>€450</td>
<td>€360</td>
</tr>
<tr>
<td><strong>REGULAR After 31 May 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physicians</td>
<td>€950</td>
<td>€760</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€865</td>
<td>€690</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant*</td>
<td>€525</td>
<td>€420</td>
</tr>
<tr>
<td>Pharmaceutical Industry Representative*</td>
<td>€950</td>
<td>€760</td>
</tr>
</tbody>
</table>

*Proof of eligibility may be required.

Register online at worldgicancer.com or call +1 678.242.0906.

Register by 11 April 2018 for the best rates.

HOTEL ACCOMMODATIONS
View hotels and make reservations online at worldgicancer.com/hotel-venue.
Reserve your place today: worldgicancer.com